2019
Mendelian randomization provides support for obesity as a risk factor for meningioma
Takahashi H, Cornish AJ, Sud A, Law PJ, Disney-Hogg L, Calvocoressi L, Lu L, Hansen HM, Smirnov I, Walsh KM, Schramm J, Hoffmann P, Nöthen MM, Jöckel KH, Schildkraut JM, Simon M, Bondy M, Wrensch M, Wiemels JL, Claus EB, Turnbull C, Houlston RS. Mendelian randomization provides support for obesity as a risk factor for meningioma. Scientific Reports 2019, 9: 309. PMID: 30670737, PMCID: PMC6343031, DOI: 10.1038/s41598-018-36186-6.Peer-Reviewed Original ResearchConceptsRisk of meningiomaMeningioma riskObesity-related traitsLipoprotein cholesterolBlood pressureRisk factorsOdds ratioLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolMendelian randomizationCause of meningiomaGenetic instrumentsDiastolic blood pressureEpidemiological observational studiesSystolic blood pressureBody mass indexBody fat percentageWaist circumferenceTotal cholesterolMass indexObservational studyMeningioma patientsMeningiomasBasal metabolic rateObesity
2012
Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females.
Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. Journal Of Neurosurgery 2012, 118: 649-56. PMID: 23101448, PMCID: PMC3756881, DOI: 10.3171/2012.9.jns12811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedBody Mass IndexBreast FeedingConnecticutContraceptives, OralEstrogen Replacement TherapyFemaleHumansMassachusettsMenarcheMeningeal NeoplasmsMeningiomaMenopauseMiddle AgedMultivariate AnalysisNorth CarolinaOdds RatioParityRegistriesReproductive HistoryRisk AssessmentRisk FactorsSan FranciscoSmokingTexasConceptsBody mass indexMeningioma riskMass indexIntracranial meningiomasExogenous hormone useHormone replacement therapyRisk of meningiomaYears of ageCurrent useResidents of ConnecticutHormone medicationWomen 29Postmenopausal womenPremenopausal womenCurrent smokingFertility medicationsOral contraceptivesHormone useMenstrual factorsSignificant positive associationCigarette smokingReplacement therapyRisk factorsReproductive factorsSignificant elevationPostmenopausal hormone therapy and ductal carcinoma in situ: A population-based case–control study
Calvocoressi L, Stowe MH, Carter D, Claus EB. Postmenopausal hormone therapy and ductal carcinoma in situ: A population-based case–control study. Cancer Epidemiology 2012, 36: 161-168. PMID: 22317899, PMCID: PMC3613248, DOI: 10.1016/j.canep.2012.01.001.Peer-Reviewed Original ResearchConceptsPopulation-based case-control studyCase-control studyHormone therapySitu breast cancerBreast cancerDuctal carcinomaRisk of DCISPostmenopausal hormone therapyFrequency-matched controlsInvasive breast cancerPost-menopausal womenDuration of usePostmenopausal womenIncident casesBreast carcinomaDCISLarger studyCarcinomaCancerImportant covariatesEstrogenTherapyAge intervalsWomenCurrent use